Divya Nag

Last updated
Divya Nag
Bornc. 1991 (age 32–33)
California
NationalityAmerican
Alma mater Stanford University
Known forFounded Stem Cell Theranostics, founded StartX Med at Stanford University
AwardsFortune 40 under 40, Silicon Valley Top 100 Innovators and Disruptors, 25 Coolest Women in Silicon Valley, Business Insider Most Powerful Millennials under 35
Scientific career
FieldsBiotechnology, stem cell biology
Institutions Apple

Divya Nag (born c. 1991) is an American stem cell biologist, biotechnology entrepreneur, and a leader of Apple's Health and Research initiatives. At the age of 20, Nag co-founded Stem Cell Theranostics which uses patient-specific stem cells in a drug discovery platform. Nag is also the founder of StartX Med, Stanford University's healthcare accelerator program. At Apple, Nag leads a team designing tools that help ease communication between healthcare professionals, researchers, and patients to guide scientific innovation and improve health outcomes.

Contents

Early life and education

Nag was born in California and grew up in El Dorado County. [1] Her parents immigrated to the United States from Jaipur, India, before she was born. [1] Nag's father, Harish Nag, is a software programmer at Intel, and he taught her from a young age to surround herself with people that are better than her. [1]

Nag attended Rolling Hills Middle School where she was the student body president. [1] At age 13, Nag she became the youngest student ever to enter Folsom Lake College. [1] With a desire to learn more and better herself, Nag then pursued high school at Mira Loma High School in Sacramento where she could partake in the International Baccalaureate Program. [1]

During her time at Mira Loma, Nag had a desire to work alongside scientists. [1] She contacted many scientists at the University of California, Davis, and secured an internship as a high school student in the lab of Alexandra Navrotsky where she explored the use of nanoparticles in the prevention of forest fires, like the ones that were ravaging her hometown at the time. [1] Her work elucidated that addition of quartz to soil would increase the temperature threshold for fires to start and now quartz is being added to prevent accidental fires in campgrounds. [1]

Nag was accepted to Stanford University in 2009 and pursued her undergraduate degree in biomedical engineering and medical anthropology. [2] She immediately started research in the lab of Joseph Wu studying stem cells, their induction, and their potential use in transplantation. [3] She also explored various aspects of cardiovascular disease. [3] Within one year she had dozens of publications and had begun to work alongside Wu and two other Stanford professors, Andrew S. Lee and Robert C. Robbins to create a drug testing platform where rapid assessment of the efficacy of drugs on human heart tissue could be tested to expedite both drug discovery and patient treatment. [4] They founded the company Stem Cell Theranostics in 2011 to begin to put their ideas to use in the healthcare sphere. [4] One year later, Nag founded StartX Med, a spin-off of the accelerator program StartX at Stanford in order to help students like herself begin the process of biotechnology innovation and healthcare entrepreneurship. [5]

By 2012, Nag was heavily involved in both Stem Cell Theranostics and StartX Med so she decided to discontinue her studies at Stanford to lead her company and organization at the age of 20. [5]

Career and research

Stem Cell Theranostics

Nag co-founded Stem Cell Theranostics in 2011. [6] Stem Cell Theranostics is a biotechnology company that pioneered the use of skin cell derived stem cells to use in drug discovery platforms. [1] Specifically, they would take skin cells and convert them to stem cells and then re-differentiate them into heart cells through the addition of transcription factors. [7] Since the heart cells, now being grown in a dish, are derived from a patient, they contain genetic profile and thus drugs can be tested in a patient specific manner. [7] The motivation behind Nag's company lies in the fact that most drugs do not make it to the final stages of clinical trials due to cardiovascular effects and further, most drugs that are recalled after passing the final stages, are recalled due to negative effects on the cardiovascular system. [7] Nag wanted a cheap and fast way to test the effects of a drug on human cells, instead of in mice, so speed up the drug discovery process and bring harmless and specific treatments to patients as quickly as possible. [8] When they tested their technology on drugs that had been recalled due to cardiovascular effects, they found that their platform identified dangerous or harmful drugs 100% of the time. [8]

StartX Med

Nag founded StartX Med at Stanford University in 2012. [9] StartX Med is an organization that supports students in their path towards innovating and developing healthcare based startup companies through Stanford. [9] She was inspired by her own experiences starting Stem Cell Theranostics as she saw added hurdles in starting a healthcare startup compared to the typical technology startup that StartX supported. [1] She wanted to help students navigate their way through finding laboratories and FDA approval as she had to for her company as well as create a collaborative environment for students interested in starting companies in the healthcare sector. [7] StartX Med has now helped over 500 health technology companies, raised over $1 billion in aggregate, and partnered with top 10 pharmaceutical companies to bring ideas into practice. [7]

Career at Apple

In 2014, Nag was recruited to work at Apple in the Special Projects unit to innovate novel ways to make healthcare data easily usable by both patients and researchers. [10] She leads a team that created ResearchKit, which is an app based tool that enables collection of health data from any user with a smartphone thus allowing researchers to broaden their subject and patient pools to expedite discovery and translation in medicine. [10] The app allows doctors to alter patients to follow their prescribed treatment plans and also allows patients to provide updates to physicians. [10] The app also allows patients to track their health and disease conditions in novel ways. [10]

Awards and honors

Select publications

Related Research Articles

<span class="mw-page-title-main">Maculopapular rash</span> Skin rash of small, raised red bumps

A maculopapular rash is a type of rash characterized by a flat, red area on the skin that is covered with small confluent bumps. It may only appear red in lighter-skinned people. The term "maculopapular" is a compound: macules are small, flat discolored spots on the surface of the skin; and papules are small, raised bumps. It is also described as erythematous, or red.

Stephen E. Epstein is the Head of Translational and Vascular Biology Research at the MedStar Heart and Vascular Institute, MedStar Washington Hospital Center and Clinical Professor of Medicine at the Georgetown University School of Medicine.

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept, though some authors and organizations differentiate between these expressions based on particular nuances. P4 is short for "predictive, preventive, personalized and participatory".

<span class="mw-page-title-main">Miller School of Medicine</span> Medical school of the University of Miami

The Miller School of Medicine, officially Leonard M. Miller School of Medicine, is the University of Miami's graduate medical school in Miami, Florida. Founded in 1952, it is the oldest medical school in the state of Florida.

<span class="mw-page-title-main">Radioimmunotherapy</span>

Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. It is a form of unsealed source radiotherapy. In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells.

Pharmacotherapy, also known as pharmacological therapy or drug therapy, is defined as medical treatment that utilizes one or more pharmaceutical drugs to improve ongoing symptoms, treat the underlying condition, or act as a prevention for other diseases (prophylaxis).

<span class="mw-page-title-main">Elizabeth Nabel</span> American academic

Elizabeth Nabel is an American cardiologist and Executive Vice President of Strategy at ModeX Therapeutics and OPKO Health. Prior to this role, she served as President of Brigham Health and its Brigham and Women's Hospital, Professor of Medicine at Harvard Medical School, and Director of the NIH's National Heart, Lung, and Blood Institute.

<span class="mw-page-title-main">Eric Topol</span> American cardiologist, scientist, and author (born 1954)

Eric Jeffrey Topol is an American cardiologist, scientist, and author. He is the founder and director of the Scripps Research Translational Institute, a professor of Molecular Medicine and Executive Vice-President at Scripps Research Institute, and a senior consultant at the Division of Cardiovascular Diseases at Scripps Clinic in La Jolla, California. He has published three bestseller books on the future of medicine: The Creative Destruction of Medicine (2010), The Patient Will See You Now (2015), and Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again (2019). He was commissioned by the UK from 2018–2019 to lead planning for the National Health Service's future workforce, integrating genomics, digital medicine, and artificial intelligence.

<span class="mw-page-title-main">Arginylglycylaspartic acid</span> Chemical compound

Arginylglycylaspartic acid (RGD) is the most common peptide motif responsible for cell adhesion to the extracellular matrix (ECM), found in species ranging from Drosophila to humans. Cell adhesion proteins called integrins recognize and bind to this sequence, which is found within many matrix proteins, including fibronectin, fibrinogen, vitronectin, osteopontin, and several other adhesive extracellular matrix proteins. The discovery of RGD and elucidation of how RGD binds to integrins has led to the development of a number of drugs and diagnostics, while the peptide itself is used ubiquitously in bioengineering. Depending on the application and the integrin targeted, RGD can be chemically modified or replaced by a similar peptide which promotes cell adhesion.

<span class="mw-page-title-main">Gladstone Institutes</span> American biomedical research organization

Gladstone Institutes is an American independent, non-profit biomedical research organization whose focus is to better understand, prevent, treat and cure cardiovascular, viral and neurological conditions such as heart failure, HIV/AIDS and Alzheimer's disease. Its researchers study these diseases using techniques of basic and translational science. Another focus at Gladstone is building on the development of induced pluripotent stem cell technology by one of its investigators, 2012 Nobel Laureate Shinya Yamanaka, to improve drug discovery, personalized medicine and tissue regeneration.

<span class="mw-page-title-main">Sanjiv Sam Gambhir</span> American physician–scientist (1962–2020)

Sanjiv Sam Gambhir was an American physician–scientist. He was the Virginia and D.K. Ludwig Professor in Cancer Research, Chairman of the Department of Radiology at Stanford University School of Medicine, and a professor by courtesy in the departments of Bioengineering and Materials Science and Engineering at Stanford University. Additionally, he served as the Director of the Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection and the Precision Health and Integrated Diagnostics Center (PHIND). He authored 680 publications and had over 40 patents pending or granted. His work was featured on the cover of over 25 journals including the Nature Series, Science, and Science Translational Medicine. He was on the editorial board of several journals including Nano Letters, Nature Clinical Practice Oncology, and Science Translational Medicine. He was founder/co-founder of several biotechnology companies and also served on the scientific advisory board of multiple companies. He mentored over 150 post-doctoral fellows and graduate students from over a dozen disciplines. He was known for his work in molecular imaging of living subjects and early cancer detection.

Stem Cell Theranostics is a privately held biotech company based out of Redwood City, California that provides drug companies with a method to more accurately predict cardiotoxicity and cardiovascular drug efficacy.

<span class="mw-page-title-main">Frank Bengel</span> German university teacher

Frank Michael Bengel is a German professor and nuclear medicine physician. He is the current director of the Department of Nuclear Medicine at the Hannover Medical School.

<span class="mw-page-title-main">Jeffrey Leiden</span> CEO of biotechnology company

Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.

Laura Elizabeth Niklason is a physician, professor and internationally recognized researcher in vascular and lung tissue engineering. She is the Nicholas M. Greene Professor of Anesthesiology and Biomedical Engineering at Yale University and co-founder, chief executive officer and president of Humacyte, a regenerative medicine company developing bioengineered human tissues.

Surgisphere is an American healthcare analytics company established in 2008 by Sapan Desai. Originally a textbook marketing company, it came under scrutiny in May 2020 after it provided large datasets of COVID-19 patients that were subsequently found to be unreliable. The questionable data were used in studies published in The Lancet and The New England Journal of Medicine in May 2020, suggesting that COVID-19 patients on hydroxychloroquine had a "significantly higher risk of death". In light of these studies, the World Health Organization decided to temporarily halt global trials of the drug hydroxychloroquine to treat COVID-19. After the studies were retracted, the WHO trials were resumed and then discontinued shortly after.

Sapan Sharankishor Desai is an American ex-physician, and the owner of Surgisphere, originally a textbook marketing company that claimed to provide large sets of medical data on COVID-19 patients. This data and the research using it has been discredited, and two papers Desai co-authored that used this data were retracted after being published in prominent medical journals.

Catherine J. Wu is an American physician-scientist who studies oncology. She is a Professor of Medicine and Chief of Division of Stem Cell Transplantation and Cellular Therapies at the Dana–Farber Cancer Institute. Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL).

Stephanie J. Lee is an American haematologist and physician scientist who is professor and associate director at the Fred Hutchinson Cancer Research Center. Lee works to improve the lives of blood stem cell transplant and bone marrow patients by better understanding the chronic form of graft-versus-host disease. Lee is the former president of the American Society of Hematology.

Theranostics, also known as theragnostics, is a technique commonly used in personalised medicine. For example in nuclear medicine, one radioactive drug is used to identify (diagnose) and a second radioactive drug is used to treat (therapy) cancerous tumors. In other words, theranostics combines radionuclide imaging and radiation therapy which targets specific biological pathways.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 Magagnini, Stephen (February 9, 2014). "Sacramento area science wunderkind gets national recognition". The Sacramento Bee. Archived from the original on 2015-09-16. Retrieved May 14, 2020.
  2. ↑ "Menlo Student Divya Nag – Forbes Pick for 30 under 30". Menlo College. 7 January 2014. Retrieved 2020-05-16.
  3. 1 2 "Divya Nag - Google Scholar Citations". scholar.google.com. Retrieved 2020-05-16.
  4. 1 2 "Stem Cell Theranostics' clinical trial in a dish". Silicon Valley Business Journal. Retrieved 2020-05-16.
  5. 1 2 3 "Divya Nag". Fortune . Retrieved 2020-05-16.
  6. ↑ "Divya Nag - A Medical Technology Enthusiast and Stem Cell Theranostics". DivyaNag. Retrieved 2020-05-16.
  7. 1 2 3 4 5 Gurman, Mark (2014-04-20). "Apple adds rising star with background in FDA approvals & product testing to medical team". 9to5Mac. Retrieved 2020-05-16.
  8. 1 2 "Divya Nag, Apple/StartX Med/Stem Cell Theranostics". FierceBiotech. Retrieved 2020-05-16.
  9. 1 2 "StartX". startx.stanford.edu. Retrieved 2020-05-16.
  10. 1 2 3 4 "Meet Divya Nag, one of Fast Company's 100 Most Creative People 2016". Fast Company . Retrieved 2020-05-16.
  11. ↑ "3 Indian-Americans Named In Time Magazine's 'Health Care 50' List". NDTV.com. Retrieved 2020-05-16.
  12. ↑ "100 Most Creative People in Business 2016". Fast Company . Retrieved 2020-05-16.
  13. ↑ Naftulin, Biz Carson, Emmie Martin, Julia. "The Silicon Valley 100: The most amazing and inspiring people in tech right now". Business Insider . Retrieved 2020-05-16.{{cite web}}: CS1 maint: multiple names: authors list (link)
  14. ↑ Naftulin, Biz Carson, Emmie Martin, Julia. "The 25 coolest women in Silicon Valley". Business Insider. Retrieved 2020-05-16.{{cite web}}: CS1 maint: multiple names: authors list (link)
  15. ↑ "30 Under 30 - Science & Healthcare". Forbes. Retrieved 2020-05-16.
  16. ↑ Levine, Jon. "Meet Divya Nag, the Millennial Woman Shaking Up US Medicine". Mic. Retrieved 2020-05-16.
  17. ↑ "2011". Joseph Wu Lab. Retrieved 2020-05-16.
  18. ↑ "Divya Nag | Society for Science & the Public" . Retrieved 2020-05-16.
  19. ↑ Perez, Marco V.; Mahaffey, Kenneth W.; Hedlin, Haley; Rumsfeld, John S.; Garcia, Ariadna; Ferris, Todd; Balasubramanian, Vidhya; Russo, Andrea M.; Rajmane, Amol; Cheung, Lauren; Hung, Grace (2019-11-14). "Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation". New England Journal of Medicine . 381 (20): 1909–1917. doi: 10.1056/NEJMoa1901183 . ISSN   0028-4793. PMC   8112605 . PMID   31722151.
  20. ↑ Turakhia, Mintu; Desai, Manisha; Hedlin, Haley; Rajmane, Amol; Talati, Nisha; Ferris, Todd; Desai, Sumbul; Nag, Divya; Patel, Mithun; Kowey, Peter; Rumsfeld, John (2018-09-01). "Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study". American Heart Journal. 207: 66–75. doi: 10.1016/j.ahj.2018.09.002 . PMC   8099048 . PMID   30392584.
  21. ↑ Nguyen, Patricia K.; Nag, Divya; Wu, Joseph C. (2012), Patterson, Cam; Willis, Monte S. (eds.), "Molecular Imaging of Cardiovascular Disease", Translational Cardiology: Molecular Basis of Cardiac Metabolism, Cardiac Remodeling, Translational Therapies and Imaging Techniques, Molecular and Translational Medicine, Humana Press, pp. 485–531, doi:10.1007/978-1-61779-891-7_14, ISBN   978-1-61779-891-7
  22. ↑ Nguyen, Patricia K.; Nag, Divya; Wu, Joseph C. (2011-02-01). "Sex differences in the diagnostic evaluation of coronary artery disease". Journal of Nuclear Cardiology. 18 (1): 144–152. doi:10.1007/s12350-010-9315-2. ISSN   1532-6551. PMC   3657505 . PMID   21136229.
  23. ↑ Nguyen, Patricia; Nag, Divya; Wu, Joseph (2010-09-30). "Methods to Assess Stem Cell Lineage, Fate and Function". Advanced Drug Delivery Reviews. 62 (12): 1175–86. doi:10.1016/j.addr.2010.08.008. PMC   3078641 . PMID   20816906.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.